




RealRate

# PHARMACEUTICAL 2022

Traverse Therapeutics Inc.  
Rank 201 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)



# PHARMACEUTICAL 2022

Traverse Therapeutics Inc.  
Rank 201 of 475



The relative strengths and weaknesses of Traverse Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Traverse Therapeutics Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 125% points. The greatest weakness of Traverse Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is -64%, being 213% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	582,827
Cost of Goods Sold	6,784
Intangible Assets	148,435
Liabilities, Current	124,088
Liabilities, Non-Current	64,152
Other Assets	34,265
Other Compr. Net Income	340
Other Expenses	22,669
Other Liabilities	286,281
Other Net Income	-17,917
Property and Equipment	11,106
Research and Development	210,328
Revenues	227,490
Selling, General and Administrative Expense	149,883

Output Variable	Value in 1000 USD
Assets	776,633
Liabilities	474,521
Expenses	389,664
Stockholders Equity	302,112
Net Income	-180,091
Comprehensive Net Income	-179,921
Economic Capital Ratio	-64%

